Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment
Colorectal Cancer|Non-Small Cell Lung Cancer|Prostate Cancer|Solid Tumors|Advanced Renal Cell Carcinoma
DRUG: Panitumumab (ABX-EGF)
To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116, Until disease progression, an AE or withdrawn consent
To assess the safety of multidose administration of panitumumab in subjects who received continued and extended panitumumab treatment, Until disease progression, an AE or withdrawn consent
A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment